Influence of ala54thr polymorphism of fatty acid-binding protein 2 on histological alterations and insulin resistance of non alcoholic fatty liver disease

European Review for Medical and Pharmacological Sciences

Volumn 13, Issue 5, 2009, Pages 357-364

  Aller, R ^a   De Luis, Daniel A ^a   Fernandez, L ^a   Calle, F ^a   Velayos, B ^a   Izaola, O ^a   Gonzalez Sagrado, M ^a   Conde, R ^a   Gonzalez, J M ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Adipokines; FABP; Histology; NAFLD

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALANINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID BINDING PROTEIN 2; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; THREONINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIETARY INTAKE; FATTY LIVER; FEMALE; FOOD; GENE EXPRESSION; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS; HISTOLOGY; HUMAN; IMPEDANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; MUTANT; NONALCOHOLIC FATTY LIVER; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WILD TYPE;

ADIPOKINES; ADULT; ALKALINE PHOSPHATASE; AMINO ACID SUBSTITUTION; ANTHROPOMETRY; ASPARTATE AMINOTRANSFERASES; FATTY ACID-BINDING PROTEINS; FATTY LIVER; FEMALE; GENOTYPE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 70450161689     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. MARCHESINI G, BUGIANESI E, FORLANI G, CERRELLI F, LENZI M, MANINI R, NATALE S, VANNI E, VILLANOVA N, MELCHIONDA N, RIZZETTO M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923. (Pubitemid 36397405)
2. LUDWIG J, VIGGIANO TR, MCGILL DB, OTT BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
3. EKSTEDT M, FRANZEN LE, MATHIESEN UL, THORELIUS L, HOLMQVIST M, BODEMAR G, KECHAGIAS S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
4. WANLESS IR, LENTZ JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
5. MARCHESINI G. MARZOCCHI R. Dietary habits, body weight and insulin resistance in non-alcoholic fatty liver disease. Endocrinol Nutr 2007; 54(Suppl 4): 5-7.
6. HUI JM, HODGE A, FARRELL GC, KENCH JG, KRIKETOS A, GEORGE J. Beyond insulin resistance in NASH: TNF-alfa or adiponectin?. Hepatology 2004; 40: 46-54. (Pubitemid 38868922)
7. NEWBERRY EP, XIE Y, KENNEDY SM, LUO J, DAVIDSON NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 2006: 44: 1191-1205.
8. BAIER LJ, SACCHETTINI JC, KNOWLER WC. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995; 95: 1281-1287.
9. DE LUIS DA, ALLER R, IZAOLA O, CONDE R, GONZALEZ M. Influence of ala54thr polymorfism of the fatty acid-binding protein 2 gene on obesity and cardiovascular risk factors. Horm Metab Res 2007; 39: 830-834.
10. BRUNT EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
11. DUART MJ, ARROYO CO, MORENO JL. Validation of a insulin model for the reactions in RIA. Clin Chem Lab Med 2002; 40: 1161-1167.
12. MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
13. PFÜTZNER A, LANGEFELD M, KUNT T, LOBIG M. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 2003; 49: 571-576.
14. MEIER U, GRESSNER M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511-1525.
15. SUOMINEN P. Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clin Chem 2004; 50: 219-221.
16. LUBRANO V, COCCI F, BATTAGLIA D, PAPA A. Usefulness of high-sensitivity IL6 measurement for clinical characterization of patients with coronary artery disease. J Clin Lab Anal 2005; 19: 110-114.
17. KHAN SS, SMITH MS, REDA D, SUFFREDINI AF, MC COY JP. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufactures. Cytometry B Clin Cytom 2004; 61: 35-39.
18. LUKASKI HC, JOHNSON PE, BOLONCHUK WW, LYKKEN GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985; 41: 810-817.
19. MATAIX J, MAÑAS M. Tablas de composición de alimentos españoles. Ed: University of Granada, 2003.
20. DIEHL AM, LI ZP, LIN HZ, YANG SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54: 303-306.
21. BATALLER R, NORTH KE, BRENNER DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493-503.
22. DIXON JB, BHATHAL PS, JONSON JR, DIXSON AF, POWELL EE, O'BRIEN PE. Profibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 2003; 39: 967-970.
23. CZAJA MJ, XU J, ALT E. Prevention of carbon tetraclhoride-induced rat liver injury by soluble tumor necrosis factor receptor. Gastroenterology 1995; 108: 1849-1854.
24. RUDIGER HA, CLAVIEN PA. Tumor necrosis factor alfa, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver. Gastroenterology 2002; 122: 202-210.
25. CARLSSON M, ORHO MELANDER M, HEDENBRO J, ALEGREN P, GROOP LC. The T54 allele of the intestinal fatty acid-binding protein 2 is associated with parenteral history of stroke. J Clin Endocr Metab 2000: 85: 2801-2804.
26. GEORGOPOULOS A, ARAS O, TSAI MY. Codon 54 polymorphism of the fatty acid binding protein 2 gene is associated with elevation of fasting and postprandial triglyceride in type 2 diabetes. J Clin Endocr Metab 2000; 85: 3155-3160.
27. GEORGOPOULOS A, ARAS O, NOUTSOU M, TSAI MY. Unlike type 2 diabetes, type 1 does not interact with the codon 54 polymorphism of the fatty acid binding protein 2 gene. J Clin Endocr Metab 2002; 87: 3735-3739.
28. STEM MP, MITCHELL DB BAGLERO J, REINHART L, KRAMMERER CM, HARRISON CR. Evidence for a major gene type II diabetes and linkage analysis with selected candidates genes in Mexican Americans. Diabetes 1996: 45: 563-568.
29. VIONNET N, HANI EH, LESAGE S, PHILIPPI A, HAGER J, VARRET M, STOFFEL M, TANIZAWA Y, CHIU KC, GLASER B, PERMUTT MA, PASSA P, DEMENAIS F, FROGUEL P. Genetics of NIDDM in France: studies with 19 candidate genes in affected sib pairs. Diabetes 1997; 46: 1062-1068.
30. DUARTE NL, COLAGIURI S, PALU T, WANG XL, WILCKEN DE. Obesity, type II diabetes and the Ala54 Thr polymorphism of fatty acid binding protein 2 in the Tongan population. Mol Genet Metab 2003: 79: 183-189.
31. DE LUIS DA, GONZÁLEZ SAGRADO M, IZAOLA O, TERROBA MC, CUELLAR L, CONDE R, MARTIN T. Influence of Ala54Thr polymorphism of fatty acid-binding protein-2 on clinical results of biliopancreatic diversion. Nutrition 2008; 24: 300-304.
32. DE LUIS DA, ALLER R, IZAOLA O, CONDE R, GONZALEZ M. Modulation of the response to a lyfestile modification in obese patients by ala54thr polymorphism of the fatty acid-binding protein 2 gene. Ann Nutr Metab 2006: 50: 354-360.
33. VALENTI L, FRACANZANI AL, DONGIOVANNI P, SANTORELLI G, BRANCHI A, TAIOLI E, FIORELLI G, FARGION S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-280.
34. SOTO A, BELLIDO D, BUÑO M, MARTINEZ OLMOS M, DE LUIS D, VIDAL O. Nonalcoholic fatty liver disease: a new component of the metabolic syndrome? Obesity and Metabolism 2006; 2: 2: 1-7.